Table 1.
Baseline characteristics of subjects stratified according to quintiles of baseline platelet count.
| Characteristics | Total patients | Platelet count quintiles, 109/L | P-value | ||||
|---|---|---|---|---|---|---|---|
| Q1 (100–155) (n = 3,296) | Q2 (156–185) (n = 3,411) | Q3 (185–212) (n = 3,348) | Q4 (213–248) (n = 3,411) | Q5 (249–450) (n = 3,376) | |||
| Age (SD), y | 64.7 (11.9) | 67.7 (11.4) | 65.8 (11.7) | 64.1 (11.6) | 63.1 (11.9) | 62.6 (12.0) | <0.001 |
| Male, n (%) | 10,617 (63.0) | 2,264 (68.7) | 2,352 (69.0) | 2,171 (64.8) | 2,076 (60.9) | 1,754 (52.0) | <0.001 |
| BMI (SD) | 24.1 (3.6) | 23.8 (3.5) | 24.0 (3.5) | 24.2 (3.6) | 24.4 (3.7) | 24.3 (3.7) | <0.001 |
| Risk factors, n (%) | |||||||
| Previous ischemic stroke | 5,144 (30.0) | 1,003 (30.4) | 1,025 (30.1) | 992 (29.6) | 1,038 (30.4) | 1,086 (32.2) | 0.203 |
| Previous myocardial infarction | 406 (2.4) | 97 (2.9) | 98 (2.9) | 76 (2.3) | 72 (2.1) | 63 (1.9) | 0.012 |
| Hypertension | 10,720 (63.7) | 2,024 (61.4) | 2,134 (62.6) | 2,123 (63.4) | 2,224 (65.2) | 2,215 (65.6) | 0.001 |
| Diabetes mellitus | 3,345 (19.9) | 674 (20.5) | 646 (18.9) | 676 (20.2) | 687 (20.1) | 662 (19.6) | 0.546 |
| Dyslipidemia | 1,923 (11.4) | 339 (10.3) | 385 (11.3) | 385 (11.5) | 403 (11.8) | 411 (12.2) | 0.153 |
| Known atrial fibrillation | 1,139 (6.8) | 320 (9.7) | 265 (7.8) | 204 (6.1) | 191 (5.6) | 159 (4.7) | <0.001 |
| Drinking | 4,679 (27.8) | 927 (28.1) | 1,042 (30.6) | 946 (28.3) | 967 (28.4) | 797 (23.6) | <0.001 |
| Previous or current smoker, (n%) | 7,320 (43.8) | 1,488 (45.2) | 1,605 (47.1) | 1,493 (44.6) | 1,497 (43.9) | 1297 (38.4) | <0.001 |
| Pre-hospital medication history | |||||||
| Antiplatelet drugs | 3,290 (19.5) | 679 (20.6) | 671 (19.7) | 601 (18.0) | 677 (19.9) | 662 (19.6) | 0.092 |
| Antihypertensive drugs | 7,430 (44.1) | 1,430 (43.4) | 1,454 (42.6) | 1,446 (43.2) | 1,581 (46.4) | 1,519 (45.0) | 0.012 |
| Lipid-lowering drug | 1,149 (6.8) | 222 (6.7) | 228 (6.7) | 220 (6.6) | 243 (7.1) | 236 (7.0) | 0.892 |
| Hypoglycemic drugs | 2,587 (15.4) | 525 (15.9) | 506 (14.8) | 522 (15.6) | 538 (15.8) | 496 (14.7) | 0.511 |
| Index event, n (%) | |||||||
| Ischemic stroke | 15,274 (90.7) | 2,995 (90.9) | 3,084 (90.4) | 3,016 (90.1) | 3,107 (91.1) | 3,072 (91.0) | 0.574 |
| TIA | 1,568 (9.3) | 301 (9.1) | 327 (9.6) | 332 (9.9) | 304 (8.9) | 304 (9.0) | |
| NIHSS score on admission, median (IQR) | 3 (1–6) | 4 (1–7) | 3 (1–6) | 3 (1–6) | 3 (1–6) | 3 (1–6) | 0.003 |
| Median time from symptom onset to admission, hours | 18.7 (4.5–50.0) | 21.0 (5.0–51.6) | 21.9 (5.5–55.0) | 22.5 (5.9–56.8) | 23.0 (5.3–57.4) | 0.022 | |
| Intravenous thrombolysis | 356 (2.1) | 71 (2.2) | 71 (2.1) | 74 (2.2) | 86 (2.5) | 54 (1.6) | 0.123 |
| Laboratory test results | |||||||
| ALT, U/L, median (IQR) | 18.0 (13.0–26.2) | 18.0 (13.0–26.4) | 18.0 (13–16) | 18.7 (13–16) | 19 (13–16) | 19 (13–16) | 0.280 |
| WBC,109/L, median (IQR) | 6.72 (5.52–8.3) | 6.0 (4.9–7.42) | 6.3 (5.3–7.8) | 5.7 (5.6–8.1) | 7.0 (5.9–8.5) | 7.6 (6.3–9.4) | <0.001 |
| CRP, mg/L, median (IQR) | 4.0 (1.8–7.4) | 4.3 (1.7–8.0) | 4.0 (1.8–7.8) | 3.6 (1.5–6.4) | 4.1 (1.8–7.0) | 4.6 (2.0–7.7) | 0.002 |
| hsCRP, mg/L, median (IQR) | 2.5 (0.9–5.8) | 2.4 (1.0–5.9) | 2.3 (0.9–5.5) | 2.5 (0.9–5.7) | 2.3 (0.8–5.2) | 2.8 (1.0–6.4) | 0.040 |
| mRS score at discharge | |||||||
| 0–2 | 13,060 (78.4) | 2,510 (77.3) | 2,654 (78.6) | 2,663 (80.3) | 2,679 (79.4) | 2,554 (76.3) | <0.001 |
| 3–5 | 3,597 (21.6) | 736 (22.7) | 721 (21.4) | 652 (19.7) | 695 (20.6) | 793 (23.7) | |
| Medication in hospital | |||||||
| Antiplatelet drugs | 14,975 (93.7) | 2,864 (92.8) | 3,036 (93.9) | 3,012 (94.1) | 3,072 (94.0) | 2,991 (93.5) | 0.165 |
| Antihypertensive drugs | 8,155 (67.0) | 1,574 (68.1) | 1,631 (66.5) | 1,563 (64.4) | 1,677 (67.6) | 1,710 (68.1) | 0.032 |
| Lipid-lowering drugs | 6,712 (92.3) | 1,095 (91.2) | 1,229 (92.6) | 1,386 (92.3) | 1,488 (92.9) | 1,451 (92.1) | 0.488 |
| Hypoglycemia drug | 2,864 (17.8) | 565 (18.2) | 571 (17.5) | 596 (18.5) | 590 (18.0) | 542 (17.0) | 0.537 |
BMI, body mass index; TIA, transient ischemic attack; ALT, alanine aminotransferase; mRS, modified Rankin Scale score; NIHSS, National Institutes of Health Stroke Scale; WBC, white blood cells; IQR, interquartile range; Q, quintile.